JPRN-jRCT2031200303已完成2 期
Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of BAY 2976217 - RE-THINc ESRD
Myoishi Masashi0 个研究点目标入组 288 人开始时间: 2021年1月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 288
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Participant must be at least 18 years of age at the time of signing the informed consent form (ICF)
- •- Participants with ESRD on hemodialysis (HD) for >=3 months at the time of signing of the ICF, receiving dialysis at least 9 hours a week and stable in the view of the investigator
- •- Male or female (contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies)
- •- Capable of giving signed ICF as described in the Protocol, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol
排除标准
- •- Participant must be at least 18 years of age at the time of signing the informed consent form (ICF)
- •- Participants with ESRD on hemodialysis (HD) for >=3 months at the time of signing of the ICF, receiving dialysis at least 9 hours a week and stable in the view of the investigator
- •- Male or female (contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies)
- •- Capable of giving signed ICF as described in the Protocol, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol
研究者
相似试验
进行中（未招募）
1 期
Factor XI LICA to reduce events such as heart attack and stroke in patientswhose kidneys are no longer able to work as they should and requiretreatment to filter wastes from the blood: Focus is on the safety ofBAY2976217 and the way the body absorbs, distributes and removes thestudy drugEnd Stage Renal Disease requiring hemodialysisMedDRA version: 21.0Level: PTClassification code 10077512Term: End stage renal diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 21.1Level: LLTClassification code 10019480Term: HemodialysisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10066639Term: Myocardial infarct prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: PTClassification code 10049165Term: Cerebrovascular accident prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2019-003927-39-DEBayer AG340
进行中（未招募）
1 期
Factor XI LICA to reduce events such as heart attack and stroke in patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood: Focus is on the safety of BAY2976217 and the way the body absorbs, distributes and removes the study drugEUCTR2019-003927-39-GRBayer AG340
进行中（未招募）
1 期
Factor XI LICA to reduce thrombotic events such as heart attack and stroke in patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood. Focus is on the safety of BAY2976217, and the way the body absorbs, distributes and gets rid of the study dug given as multiple dosesEUCTR2019-003927-39-LVBayer AG340
进行中（未招募）
1 期
Factor XI LICA to reduce thrombotic events such as heart attack and stroke in patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood. Focus is on the safety of BAY2976217, and the way the body absorbs, distributes and gets rid of the study drug given as multiple dosesEUCTR2019-003927-39-HUBayer AG340
进行中（未招募）
1 期
Factor XI LICA to reduce thrombotic events such as heart attack and stroke in patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood. Focus is on the safety of BAY2976217, and the way the body absorbs, distributes and removes the study drugEnd Stage Renal Disease requiring hemodialysisMedDRA version: 21.0Level: PTClassification code 10077512Term: End stage renal diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 21.1Level: LLTClassification code 10019480Term: HemodialysisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10066639Term: Myocardial infarct prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: PTClassification code 10049165Term: Cerebrovascular accident prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2019-003927-39-BGBayer AG340